Cargando…

Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

Anemia is a common complication of chronic kidney disease (CKD), with erythropoietin deficiency being the major contributing factor. The availability of erythropoiesis-stimulating agents (ESAs) has been a seminal advance in the treatment of anemia related to chronic kidney disease. Over the course o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panchapakesan, Usha, Sumual, Siska, Pollock, Carol
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673829/ https://www.ncbi.nlm.nih.gov/pubmed/17722510

Ejemplares similares

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia
por: Duman, Neval, et al.
Publicado: (2014)

Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis
por: Vankar, Sameer G., et al.
Publicado: (2014)

Cost-effectiveness of continuous erythropoietin receptor activator in anemia
por: Schmid, Holger
Publicado: (2014)

Persona di cera/
por: Tynianov, IU. N. 1894-1943 (IUrii Nikolaevich)

Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials
por: Locatelli, Francesco, et al.
Publicado: (2016)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

El museo de cera
por: Edwards, Jorge
Publicado: (1997)

El museo de cera
por: Edwards, Jorge
Publicado: (1981)

Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation
por: Fujimoto, Daisuke, et al.
Publicado: (2020)

Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
por: Oh, Jieun, et al.
Publicado: (2014)

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
por: Hirsh, Vera, et al.
Publicado: (2007)

Museo de cera ; manual de exploradores, 1960-1972
por: Alvarez, José María, 1942-
Publicado: (1974)

Hombres con alas de cera /
por: Cruz Oliva, Oscar René
Publicado: (2003)

A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia
por: Sezai, Akira, et al.
Publicado: (2023)

Lipocalin-2, Soluble Transferrin Receptor, and Erythropoietin in Anemia During Mild Renal Dysfunction
por: Nahm, Chung Hyun, et al.
Publicado: (2023)

La cera en México : arte e historia
por: Esparza Liberal, María José
Publicado: (1994)

Nanomedicines in renal transplant rejection – focus on sirolimus
por: Shen, Li-Jiuan, et al.
Publicado: (2007)

Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin
por: Gangadharan Komala, Muralikrishna, et al.
Publicado: (2015)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Santo en el museo de cera
Publicado: (2003)

CERA Attenuates Kidney Fibrogenesis in the db/db Mouse by Influencing the Renal Myofibroblast Generation
por: Fischer, Christin, et al.
Publicado: (2018)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Erythropoietin in the intensive care unit: beyond treatment of anemia
por: Patel, Nimesh SA, et al.
Publicado: (2011)

Cost-Effectiveness and Resource Allocation (CERA) – directions for the future
por: Baltussen, Rob, et al.
Publicado: (2009)

Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease
por: Khankin, Eliyahu V., et al.
Publicado: (2010)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
por: Zheng, Xiaomeng, et al.
Publicado: (2023)

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
por: Budde, Klemens, et al.
Publicado: (2014)

Uso de las ceras en el laboratorio dental /
por: Toral Aburto, Wendy Jessica
Publicado: (2005)

Qairooti (Cerate or Cera Beeswax Salve) in Traditional Iranian Pharmacy
por: Mosleh, Ghazaleh, et al.
Publicado: (2016)

Isolation and Characterization of Renal Erythropoietin-Producing Cells from Genetically Produced Anemia Mice
por: Pan, Xiaoqing, et al.
Publicado: (2011)

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients
por: Nasri, Hamid
Publicado: (2014)

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction
por: Debeljak, Nataša, et al.
Publicado: (2014)

Focus on nanomedicine molecular science
por: Ishihara, Kazuhiko, et al.
Publicado: (2016)

Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study
por: Jin, Chen, et al.
Publicado: (2022)

Cutaneous leukocytoclastic vasculitis induced by continuous erythropoietin receptor activator
por: Kwon, Hyeok-Jin, et al.
Publicado: (2021)

The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients
por: Maoujoud, Omar, et al.
Publicado: (2016)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose
por: Salheen, Salheen M., et al.
Publicado: (2015)

Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
por: Olver, Ian, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_dd2b0ap7q3uaqk8pca1nilndc3